Reddy B S, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G
Division of Nutrition and Endocrinology, Naylor Dana Institute for Disease Prevention, American Health Foundation, Valhalla, New York 10595.
Cancer Res. 1990 May 1;50(9):2562-8.
The effect of three levels of piroxicam and three levels of D,L-alpha-difluoromethylornithine (DFMO) fed individually and in combination during the postinitiation phase of carcinogenesis was studied in male F344 rats to generate a data base on the efficacy and synergistic and additive effects of these compounds as inhibitors of colon carcinogenesis. The maximum tolerated dose of DFMO was determined in male F344 rats and found to be 5000 ppm in the AIN-76A diet. Piroxicam at levels of 25, 75, and 150 ppm and DFMO at concentrations of 400, 1000, and 4000 ppm (20, 50, and 80% maximum tolerated dose) in AIN-76 diet were tested individually and in combinations. At 7 weeks of age, while the rats were consuming the control diet (AIN-76A), all animals except the vehicle (saline)-treated controls were given a single s.c. injection of azoxymethane (CAS: 25843-45-2) at a dose level of 29.6 mg/kg body weight to induce intestinal tumors. One week after azoxymethane injection, animals were transferred to their respective experimental diets containing piroxicam and DFMO. Fifty-six weeks after azoxymethane injection, all animals were necropsied and colon and small intestinal tumor incidences and multiplicity were compared among the various dietary groups. Feeding of diets containing 75 and 150 ppm piroxicam or 1000 and 4000 ppm DFMO significantly inhibited the incidence (percentage of animals with tumors) of colon adenocarcinomas compared to that of control diet. The multiplicity (number of tumors/rat) of adenocarcinomas was significantly inhibited in animals fed the 25, 75, and 150 ppm piroxicam or 400, 1000, and 4000 ppm DFMO diets. Results analyzed by the linear regression method suggested a dose-dependent inhibition in colon adenocarcinoma incidence with increasing levels of piroxicam or DFMO. The incidence and multiplicity of colon adenocarcinomas were significantly inhibited in animals fed the diets containing combinations of 25, 75, and 150 ppm piroxicam and 400, 1000, and 4000 ppm DFMO. Piroxicam and DFMO administered together had a stronger inhibitory effect than did those given individually. Piroxicam and DFMO when administered individually had no significant inhibitory effect on colon adenoma incidence and multiplicity; in contrast, combinations of these compounds significantly inhibited colon adenomas. No consistent differences were found in the incidence and multiplicity of small intestinal tumors among the dietary groups.(ABSTRACT TRUNCATED AT 400 WORDS)
在雄性F344大鼠致癌起始后阶段,研究了单独及联合给予三种剂量的吡罗昔康和三种剂量的D,L-α-二氟甲基鸟氨酸(DFMO)的效果,以建立关于这些化合物作为结肠癌发生抑制剂的功效、协同和相加作用的数据库。测定了雄性F344大鼠DFMO的最大耐受剂量,发现在AIN - 76A饮食中为5000 ppm。测试了AIN - 76饮食中25、75和150 ppm水平的吡罗昔康以及400、1000和4000 ppm(20%、50%和80%最大耐受剂量)浓度的DFMO,单独及联合给药的情况。7周龄时,当大鼠食用对照饮食(AIN - 76A)时,除溶剂(生理盐水)处理的对照外,所有动物均皮下注射一次剂量为29.6 mg/kg体重的偶氮甲烷(CAS:25843 - 45 - 2)以诱导肠道肿瘤。偶氮甲烷注射一周后,将动物转移至各自含吡罗昔康和DFMO的实验饮食中。偶氮甲烷注射56周后,对所有动物进行尸检,并比较不同饮食组的结肠和小肠肿瘤发生率及肿瘤数量。与对照饮食相比,喂食含75和150 ppm吡罗昔康或1000和4000 ppm DFMO的饮食显著抑制了结肠腺癌的发生率(患肿瘤动物的百分比)。喂食25、75和150 ppm吡罗昔康或400、1000和4000 ppm DFMO饮食的动物,腺癌的肿瘤数量(每只大鼠的肿瘤数)显著减少。线性回归分析结果表明,随着吡罗昔康或DFMO水平的增加,结肠腺癌发生率呈剂量依赖性抑制。喂食含25、75和150 ppm吡罗昔康与400、1000和4000 ppm DFMO组合饮食的动物,结肠腺癌的发生率和肿瘤数量显著降低。吡罗昔康和DFMO联合给药比单独给药具有更强的抑制作用。吡罗昔康和DFMO单独给药时对结肠腺瘤的发生率和肿瘤数量无显著抑制作用;相比之下,这些化合物的组合显著抑制了结肠腺瘤。各饮食组小肠肿瘤的发生率和肿瘤数量未发现一致差异。(摘要截短至400字)